BRAINP Stock Overview
Brain+ A/S develops digital therapeutics for Alzheimer’s and dementia.
Price History & Performance
|Historical stock prices|
|Current Share Price||kr.2.58|
|52 Week High||kr.5.10|
|52 Week Low||kr.2.02|
|1 Month Change||1.58%|
|3 Month Change||-11.03%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-41.36%|
Recent News & Updates
|BRAINP||DK Healthcare Services||DK Market|
Return vs Industry: Insufficient data to determine how BRAINP performed against the Danish Healthcare Services industry.
Return vs Market: Insufficient data to determine how BRAINP performed against the Danish Market.
|BRAINP Average Weekly Movement||14.0%|
|Healthcare Services Industry Average Movement||7.5%|
|Market Average Movement||6.5%|
|10% most volatile stocks in DK Market||10.8%|
|10% least volatile stocks in DK Market||3.9%|
Stable Share Price: BRAINP is more volatile than 90% of Danish stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: BRAINP's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Danish stocks.
About the Company
Brain+ A/S develops digital therapeutics for Alzheimer’s and dementia. The company develops cognitive stimulation therapy (CST), a therapy that treats the main symptoms of dementia; Computerized Cognitive Training, a cognitive training method for patients with mild cognitive impairment; and Starry Night, memory test for early detection and monitoring of Alzheimer’s. In addition, it develops an interface for clinicians to track and trace the patient’s treatment progress.
Brain+ Fundamentals Summary
|BRAINP fundamental statistics|
Is BRAINP overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BRAINP income statement (TTM)|
|Cost of Revenue||kr.0|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.60|
|Net Profit Margin||-177.34%|
How did BRAINP perform over the long term?See historical performance and comparison
Is Brain+ undervalued compared to its fair value and its price relative to the market?
Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate BRAINP's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate BRAINP's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: BRAINP is unprofitable, so we can't compare its PE Ratio to the European Healthcare Services industry average.
PE vs Market: BRAINP is unprofitable, so we can't compare its PE Ratio to the Danish market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BRAINP's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BRAINP is good value based on its PB Ratio (1.5x) compared to the XE Healthcare Services industry average (2.7x).
How is Brain+ forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Brain+ has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Brain+ performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BRAINP is currently unprofitable.
Growing Profit Margin: BRAINP is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BRAINP is unprofitable, and losses have increased over the past 5 years at a rate of 55% per year.
Accelerating Growth: Unable to compare BRAINP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BRAINP is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (-3%).
Return on Equity
High ROE: BRAINP has a negative Return on Equity (-34.36%), as it is currently unprofitable.
How is Brain+'s financial position?
Financial Health Score3/6
Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: BRAINP's short term assets (DKK13.3M) do not cover its short term liabilities (DKK24.5M).
Long Term Liabilities: BRAINP's short term assets (DKK13.3M) exceed its long term liabilities (DKK1.8M).
Debt to Equity History and Analysis
Debt Level: BRAINP has more cash than its total debt.
Reducing Debt: Insufficient data to determine if BRAINP's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BRAINP has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: BRAINP has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 200.1% each year.
What is Brain+ current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BRAINP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BRAINP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BRAINP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BRAINP's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as BRAINP has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Kim Baden-Kristensen is Founder, Chief Executive Officer and Managing Director of Brain+ ApS. He is Co-Founder and Chief Executive Officer of Brain+ A/S. He began his career in high tier strategic mana...
Experienced Management: BRAINP's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Experienced Board: BRAINP's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: BRAINP only recently listed within the past 12 months.
Brain+ A/S's employee growth, exchange listings and data sources
- Name: Brain+ A/S
- Ticker: BRAINP
- Exchange: CPSE
- Founded: 2012
- Industry: Health Care Technology
- Sector: Healthcare
- Implied Market Cap: kr.30.485m
- Shares outstanding: 11.82m
- Website: https://www.brain-plus.com
Number of Employees
- Brain+ A/S
- KOebmagergade 53
- 3rd floor
- Capital Region of Denmark
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/20 00:00|
|End of Day Share Price||2022/05/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.